Objective: To present a case series of patients with progressive myelopathy in the setting of a solitary demyelinating lesion.
Progressive myelopathy is a frequent manifestation of primary and secondary progressive multiple sclerosis (MS), but progressive neurologic deficit resulting from a single, spatially isolated demyelinated lesion is not well-recognized. Current International Panel diagnostic criteria permit a diagnosis of MS in patients with isolated clinical findings of progressive myelopathy but also require 2 of 3 additional paraclinical criteria to establish dissemination in space (one or more T2 brain lesions in an area characteristic for MS, 2 or more T2 spinal cord lesions, or CSF demonstrating either intrathecal oligoclonal bands or elevation in the CSF immunoglobulin G index). 1 We describe 7 patients with progressive myelopathy referable to a solitary demyelinating lesion within the brainstem or upper cervical cord without clinical or radiologic evidence of dissemination in space.
Median numbers of serial MRI studies of the brain and cervical and thoracic spine available for review at the time of evaluation were as follows: brain, 2 (range 1-5); cervical spine, 2 (range 1-6); and thoracic spine, 2 (range 0 -3). Results of CSF examination were available for 6 patients. Four had pattern reversal visual evoked potential studies, and 2 had somatosensory evoked potential studies. Results of additional serologic studies are discussed subsequently. We also obtained follow-up medical histories by telephone from 4 patients in 2010. One patient previously died while under our care, one declined to participate in the telephone follow-up and one could not be located.
Standard protocol approvals, registrations, and patient consents. The study was approved by the Mayo Clinic Institutional Review Board (IRB 09-007045). Written informed consent was obtained from patients participating in the telephone follow-up portion of the study.
RESULTS
Clinical characteristics. Clinical histories are summarized in table 1. Four of 7 patients (57%) were women. The median age at onset of first symptom was 43 years (range 25-51 years) and median age at onset of progressive myelopathy was 43 years (range 37-54 years). Three patients had insidiously progressive symptoms at onset. One had subacute symptoms of an inflammatory myelopathy with incomplete resolution and then developed progressive myelopathy within 6 months of symptom onset. Before onset of progression, 3 patients had episodic neurologic symptoms with subsequent resolution referable to the lesion visualized on MRI. Five patients developed quadriparesis, and 2 patients developed hemiparesis. All patients had neurogenic bladder dysfunction; one had bowel incontinence. Five had objective sensory abnormalities, predominantly consisting of distal sensory impairment in the limbs affected by motor symptoms. Posterior column modalities were affected in 4 of 7 patients (57%) and spinothalamic modalities in 3 of 7 patients (43%); in all but one patient the degree of objective sensory impairment was mild.
Neuroimaging. The MRI abnormalities observed in patients 2-7 are shown in the figure. (Patient 1 underwent MRI of the brain and cervical spine, but the images are no longer available.) At the time of clinic evaluation, 2 or more serial MRI scans of the brain and entire spinal cord had been performed for patients 5, 6, and 7 (table 2). None of the serial images revealed accumulation of new lesions. Serial MRI imaging was not performed for patient 1, but postmortem evaluation of the brain and spinal cord revealed a solitary demyelinating lesion in the pons with no other evidence of CNS demyelination. Patient outcomes and follow-up. Six of 7 patients have reached EDSS score of 6.0 or worse. From onset of symptoms, median time to reach an EDSS score of 6.0 was 7.5 years (range 1.5-26 years). One patient died from a complication of myelopathy (candidal urosepsis in the setting of neurogenic bladder) and 2 other patients have become quadriplegic and dependent on others for basic activities of daily living (EDSS score of 9.0). Three patients were not treated with any immunosuppressant or immunomodulatory medications at any time. Before evaluation in our clinic, the other patients received a variety of treatments as listed in table 1; each continued to experience progressive neurologic decline despite these interventions.
The DISCUSSION There are many reasons to believe that the patients we report with solitary sclerosis have inflammatory demyelinating disease, similar to MS. The lesions visualized on MRI resemble typical demyelinating plaques: circumscribed, nonlongitudinally extensive T2 hyperintense lesions not occupying the entire cord or medulla in axial crosssection and associated with no or minimal mass effect. The majority of patients had CSF or electrodiagnostic findings characteristic of MS. The median age at onset of progressive symptoms in these patients was quite similar to that reported for onset of progressive symptoms in patients with MS. 2 The clinical phenotypes were generally similar to those of either primary progressive or single-attack progressive MS. 2 Other conditions frequently associated with myelopathy are not likely diagnoses in these patients. None of the patients had a longitudinally extensive (Ն3 vertebral segments in length) T2 signal abnormality characteristic of a NMO spectrum disorder; in addition, progressive myelopathy is distinctly unusual in NMO. 3 The progressive course is highly atypical for cord ischemia, as are the age of the patients and lack of significant vascular risk factors. We found no evidence of an infectious, paraneoplastic, metabolic, or inflammatory connective tissue disorder in any patient. None had significant spinal trauma or spinal stenosis. We hypothesize that these patients represent a spatially limited variant of MS. The retrospective identification of cases from the observations of the authors at a specialty MS clinic does not allow for an accurate estimation of the prevalence of this particular presentation in the general population. The solitary sclerosis phenotype we describe is unusual and numerically may not merit an independent category. However, these patients indicate that inflammatory demyelinating disease can and should be included in the differential diagnosis of progressive myelopathy even in the absence of dissemination of lesions in space, which remains a requirement of existing international criteria for diagnosis of progressive MS. 1 Failure to recognize that progressive demyelinating disease can present as a solitary lesion could lead to erroneous diagnosis of a condition that more typically presents as a solitary lesion, such as a neoplasm. Patient 7 had been advised to undergo spinal radiotherapy for a suspected low-grade glial tumor.
The identification of a number of patients with solitary lesions at the cervicomedullary junction may reflect the propensity of critically placed lesions at this site to produce progressive myelopathy because of the concentration of functionally critical tracts. This factor may also account for the marked clinical severity noted in several patients in this cohort. Solitary demyelinating lesions may occur at other sites, but because they might be clinically silent or produce symptoms less suggestive of demyelinating disease, imaging and other studies to establish a firm diagnosis of inflammatory demyelinating disease may not be performed.
The pathophysiologic basis of axonal degeneration in these patients and in MS in general is unclear. Demyelinated lesions do not invariably result in progressive axonal degeneration, and correlations between the amount of demyelination and degree of axon injury in MS pathology cohorts are modest. 4 These patients could represent a subset of patients with spatially limited demyelination who developed axon degeneration on the basis of other secondary factor(s), such as failure of remyelination or attack of axons by other immune effectors. Primary axonal degeneration at sites distant from the focus of demyelination is also conceivable, although in these patients the clinical symptoms appeared to correspond to the location of the visualized lesion.
One prior case series described 4 patients with monosymptomatic progressive myelopathy due to apparent demyelinating disease; however, 2 of these patients had radiologic evidence of dissemination of asymptomatic CNS demyelinating lesions in space and another was investigated only with low-field (0.15-T) MRI. 5 Likewise, other patients in our cohort could have more demyelinating lesions detected with repeat or higher resolution MRI imaging, as noted for patient 2. However, persistence of clinical and radiologic spatial isolation over many years in the remainder of patients and the finding of an isolated demyelinating lesion on postmortem examination in one patient suggest that progressive neurologic symptoms may occur in the context of a solitary demyelinating focus.
As in other progressive subtypes of MS, 6 -8 immunosuppressive and immunomodulatory therapies did not appear to alter the ongoing worsening of neurologic deficits in these patients. In the absence of a controlled study, it is impossible to exclude a beneficial effect in this setting.
